GlassScriptPhysician profile
Merrill Ansher
NPI 1932176294
$6,552.78
in general payments reported to CMS, 2019-2025
43 companies · $16.15 in 2025
The $16.15 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,480 · 2020: $1,952 · 2021: $1,914 · 2022: $78.42 · 2023: $68.20 · 2024: $44.27 · 2025: $16.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $128.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $791.17 | 2019-2021 | |
| Biogen, INC. | $707.20 | 2019-2021 | |
| Allergan, INC. | $531.75 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $457.73 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $391.54 | 2019-2020 | |
| Ucb, INC. | $376.85 | 2019-2021 | |
| Abbvie INC. | $254.98 | 2021-2023 | Botox |
| Alexion Pharmaceuticals, INC. | $250.26 | 2019-2020 | |
| Genzyme Corporation | $245.96 | 2019-2023 | |
| Lilly USA, LLC | $241.26 | 2019-2021 | |
| Amgen INC. | $213.68 | 2019-2025 | Uplizna |
| Emd Serono, INC. | $206.83 | 2019-2020 | |
| Eisai INC. | $206.13 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $204.07 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $129.18 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merrill Ansher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.